Our Mission
GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages.
The Galleri test is a multi-cancer early detection (MCED) blood test that screens for cancers before they become symptomatic, including those we don’t have recommended screening tests for today.
The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur.
Adding a blood-based multi-cancer early detection test can help screen for many of the deadliest cancers that don’t have recommended screening today.
Who We Are
GRAIL is a healthcare company innovating to solve healthcare’s most important challenges. Our team of leading scientists, engineers and clinicians are on an urgent mission to detect cancer early, when it may be more treatable and potentially curable.
